Deleterious impact of mild anemia on survival of young adult patients (age 45 ± 14 years) with idiopathic dilated cardiomyopathy: data from the Trieste Cardiomyopathies Registry

Heart Lung. 2011 Sep-Oct;40(5):454-61. doi: 10.1016/j.hrtlng.2010.06.001. Epub 2010 Aug 17.

Abstract

Objective: The study objective was to evaluate the impact of anemia on a large population of young patients with idiopathic dilated cardiomyopathy (DCM) who were receiving optimal medical treatment.

Methods: The data of 491 patients with DCM who were enlisted in the Trieste Heart Muscle Disease Registry were analyzed. Anemia was defined as hemoglobin less than 13 g/dL for male patients and less than 12 g/dL for female patients.

Results: At baseline, 13% of our patients were anemic. During the follow-up of 134 ± 56 months, 144 patients died or underwent heart transplantation: 36.5% anemic patients and 28% non-anemic patients (P = .05). Anemia present at baseline was an independent predictor of outcome (hazard ratio = 1.85, P = .014). Serial hemoglobin determinations during the entire follow-up were available in 122 of 428 patients without anemia at baseline. The impact of new-onset anemia was analyzed in this cohort of patients. Forty-seven patients (39%) developed anemia during follow-up. The new onset of anemia was an independent predictor of poor outcome (hazard ratio = 2.85, P = .02).

Conclusion: The presence or development of mild anemia in young patients with optimally treated idiopathic DCM is frequent and associated with a worse outcome.

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Anemia / complications*
  • Anemia / epidemiology
  • Anemia / pathology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Cardiomyopathy, Dilated / drug therapy
  • Cardiomyopathy, Dilated / mortality*
  • Cardiomyopathy, Dilated / pathology
  • Female
  • Humans
  • Italy / epidemiology
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Prognosis
  • Registries
  • Retrospective Studies
  • Statistics as Topic
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors